title: Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice.
abstract: Butyrate and butyric acid derivatives are well known to induce differentiation and apoptosis of tumor cells and have also recently gained acceptance as potential anticancer agents. In this study we observed an increased expression of mTNFalpha in tumor tissues in mice treated with butyrate prodrug tributyrin. Since in in vitro experiments we observed a potentiating effects of TNFalpha and actinomycin D on B16F10 cells and also a synergistic interaction was previously claimed between those agents, we investigated the anti-tumor activity of the combination therapy with butyrate and actinomycin D in the B16F10 melanoma model in mice. The combination of the drugs resulted in a strongly potentiated tumor growth retardation in melanoma bearing mice. However the B16F10 cells in vitro did not produce any detectable amounts of TNFalpha. The presented data strongly suggest that one of the mechanism of this successful drug combination could depend on the interaction of the actinomycin D with butyrate-induced TNFalpha produced by stromal or tumor infiltrating immune cells. The results illustrate also the possible application of this combination in cancer therapy.
authors.affiliation: Department of Immunology, Center of Biostructure Research, The Medical University of Warsaw, 02-004 Warsaw, Poland.
authors.forename: Adam
authors.initials: A
authors.lastname: Giermasz
authors.forename: Marcin
authors.initials: M
authors.lastname: Makowski
authors.forename: Dominika
authors.initials: D
authors.lastname: Nowis
authors.forename: Ahmad
authors.initials: A
authors.lastname: Jalili
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Maj
authors.forename: Anna
authors.initials: A
authors.lastname: Dabrowska
authors.forename: Anna
authors.initials: A
authors.lastname: Czajka
authors.forename: Marek
authors.initials: M
authors.lastname: Jakobisiak
authors.forename: Jakub
authors.initials: J
authors.lastname: Golab
mesh_terms: D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D003609:Dactinomycin / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005562:Formazans; D008297:Male; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D013778:Tetrazolium Salts; D014280:Triglycerides / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D005562:Formazans; D013778:Tetrazolium Salts; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D003609:Dactinomycin; C079782:MTT formazan; C005830:tributyrin